rsv – Scalper1

J&J’s Alios Buyout Bodes Interesting Times For Gilead

The drama continued for big biotech Gilead Sciences Tuesday, as Johnson & Johnson moved into its viral-disease turf on two fronts with an acquisition. Johnson & Johnson (JNJ) disclosed that it’s buying privately held Alios BioPharma for $1.75 billion in cash. In a press release, J&J touted Alios’ drug candidate for respiratory syncytial virus (RSV), a major cause of lung infection that has no current treatment. The drug, AL-8176, is

J&J Buying Alios, Going Up Against Gilead

Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In a press release, J&J touted Alios’ drug candidate for respiratory syncytial virus (RSV), a major cause of lung infections that has no current treatment. The drug, AL-8176, is in midstage clinical